

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7684654

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KOLBOT BY	11/29/2022
PASIT PHIASIVONGSA	11/01/2022
JIANG ZHU	11/02/2022
MOHAMMAD MASJEDIZADEH	11/09/2022
RECEIVING PARTY DATA	
Name:	PRINCIPIA BIOPHARMA INC.
Street Address:	220 EAST GRAND AVENUE
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17143355
CORRESPONDENCE DATA	
Fax Number:	(617)812-1277
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174304740
Email:	DOCKETING@MCNEILLBAUR.COM
Correspondent Name:	MCNEILL BAUR PLLC
Address Line 1:	125 CAMBRIDGE PARK DRIVE
Address Line 2:	SUITE 301
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02140
ATTORNEY DOCKET NUMBER:	01183-0134-00US-PRN
NAME OF SUBMITTER:	CHRISTINE DONAHUE
SIGNATURE:	/christine donahue/
DATE SIGNED:	12/08/2022
Total Attachments: 5	
source=2022-12-05_01183-0134-00US-PRN_Assignment-signed by all inventors (1)#page1.tif	
source=2022-12-05_01183-0134-00US-PRN_Assignment-signed by all inventors (1)#page2.tif	

source=2022-12-05_01183-0134-00US-PRN_Assignment-signed by all inventors (1)#page3.tif

source=2022-12-05_01183-0134-00US-PRN_Assignment-signed by all inventors (1)#page4.tif

source=2022-12-05_01183-0134-00US-PRN_Assignment-signed by all inventors (1)#page5.tif

ASSIGNMENT

WHEREAS WE are the below-named inventors (hereinafter referred to as Assignors) of an invention entitled:

CRYSTALLINE FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4,4-DIMETHYLPENT-2-ENENITRILE

as disclosed and claimed in the applications identified below this paragraph:

Application Number	Country of Filing	Filing Date
62/958,389	US	January 8, 2020
17/143,355	US	January 7, 2021
PCT/US2021/012515	WO	January 7, 2021
110100559	TW	January 7, 2021
P 21 01 00033	AR	January 7, 2021
2021/41268	GC	January 4, 2021

by virtue of our agreements with Principia Biopharma Inc., a corporation of Delaware whose post office address is 220 E. Grand Avenue, South San Francisco, CA 94080, USA (hereinafter referred to as Assignee), confirm assignment and hereby assign to Assignee the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, WE, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and WE hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE covenant that WE have the full right to convey the interest assigned by this Assignment, and WE have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE further covenant and agree that WE will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, WE have hereunto set our hands.

ASSIGNOR (Inventor) 3




Signature

Kolbot By
Print Name

29 Nov 2022

Execution Date

ASSIGNOR (Inventor) 1



Signature


Pasit Phiasivongsa

Print Name

01 Nov 2022

Execution Date

ASSIGNOR (Inventor) 2



Signature


Jiang Zhu

Print Name

Nov-2-2022

Execution Date

ASSIGNOR (Inventor) 4



Signature

Mohammad Masjedizadeh

Print Name

11-9-2022

Execution Date